Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC–MS/MS Reference Method
Abstract
Cerebrospinal fluid (CSF) amyloid-β1-42 (Aβ42) reliably detects brain amyloidosis based on its high concordance with plaque burden at autopsy and with amyloid positron emission tomography (PET) ligand retention observed in several studies. Low CSF Aβ42 concentrations in normal aging and dementia are associated with the presence of fibrillary Aβ across brain regions detected by amyloid PET imaging.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 31, 2020
- Source ID
- 10.1093/clinchem/hvaa012
Entities
People
- For The Alzheimer’s Disease Neuroimaging Initiative*
- Henrik Zetterberg
- Jacob Alexander
- John Q. Trojanowski
- Kaj Blennow
- Leslie M. Shaw
- Magdalena Brylska
- Magdalena Korecka
- Michal J. Figurski
- Susan M. Landau
- William J. Jagust
Organizations
- AbbVie
- Alzheimer's Disease Neuroimaging Initiative
- Helen Wills Neuroscience Institute
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Sahlgrenska University Hospital
- United States Department of Defense
- University College London
- University of Pennsylvania